|
A Novel Molecular-Targeted Prognostic Immunohistochemistry Test for the Risk Profiling of ER+ Breast Cancer Patients
Mammostrat is a five-antibody prognostic test for estrogen receptor-expressing, hormone receptor-treated (tamoxifen) breast cancer patients with node-negative disease.
Mammostrat utilizes standard paraffin-embedded tissue. The tissue is stained with five monoclonal antibodies to classify the patient as having a low, moderate or high risk of disease recurrence. The results of Mammostrat's definitive validation study conducted on 711 patients from the NSABP (National Surgical Adjuvant Breast and Bowel Project) B14 and B20 trials indicated that postmenopausal patients in the low-risk category have a seven percent probability of distant recurrence over a 10-year period.1,2
The Mammostrat test has been clinically validated in four independent institutional cohorts. For details refer to: JCO 2006, ASCO 2006, SABCS 2006.
For further information visit our official Mammostrat website www.mammostrat-us.com.
References :
1. Ring, B. Z., et al. 2006. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. Journal of Clinical Oncology. 24(19):3039-47.
2. Ross, D. T., et al. Validation of a prognostic algorithm based upon a five monoclonal antibody immunohistochemistry test in Tamoxifen-treated, node negative breast cancer: NSABP B14 and B20 studies. Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 2006.
"This test was developed by Applied Genomics and its performance characteristics determined by Applied Genomics and the Molecular Profiling Institute, Inc. (MP). This test is performed at MP. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined that such approval is not necessary. This test is permitted for clinical purposes and should not be regarded as purely investigational or for research. MP is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing."
|
|
|
|
